Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
T cells enhance stem-like properties and conditional malignancy in gliomas.
Irvin DK, Jouanneau E, Duvall G, Zhang XX, Zhai Y, Sarayba D, Seksenyan A, Panwar A, Black KL, Wheeler CJ. Irvin DK, et al. Among authors: duvall g. PLoS One. 2010 Jun 7;5(6):e10974. doi: 10.1371/journal.pone.0010974. PLoS One. 2010. PMID: 20539758 Free PMC article.
Functional recreation of age-related CD8 T cells in young mice identifies drivers of aging- and human-specific tissue pathology.
Panwar A, Jhun M, Rentsendorj A, Mardiros A, Cordner R, Birch K, Yeager N, Duvall G, Golchian D, Koronyo-Hamaoui M, Cohen RM, Ley E, Black KL, Wheeler CJ. Panwar A, et al. Among authors: duvall g. Mech Ageing Dev. 2020 Oct;191:111351. doi: 10.1016/j.mad.2020.111351. Epub 2020 Sep 8. Mech Ageing Dev. 2020. PMID: 32910956 Free PMC article.
Antigen-specific age-related memory CD8 T cells induce and track Alzheimer's-like neurodegeneration.
Panwar A, Rentsendorj A, Jhun M, Cohen RM, Cordner R, Gull N, Pechnick RN, Duvall G, Mardiros A, Golchian D, Schubloom H, Jin LW, Van Dam D, Vermeiren Y, De Reu H, De Deyn PP, Raskatov JA, Black KL, Irvin DK, Williams BA, Wheeler CJ. Panwar A, et al. Among authors: duvall g. bioRxiv [Preprint]. 2024 Jan 22:2024.01.22.576704. doi: 10.1101/2024.01.22.576704. bioRxiv. 2024. Update in: Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2401420121. doi: 10.1073/pnas.2401420121 PMID: 38328072 Free PMC article. Updated. Preprint.
Antigen-specific age-related memory CD8 T cells induce and track Alzheimer's-like neurodegeneration.
Panwar A, Rentsendorj A, Jhun M, Cohen RM, Cordner R, Gull N, Pechnick RN, Duvall G, Mardiros A, Golchian D, Schubloom H, Jin LW, Van Dam D, Vermeiren Y, De Reu H, De Deyn PP, Raskatov JA, Black KL, Irvin DK, Williams BA, Wheeler CJ. Panwar A, et al. Among authors: duvall g. Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2401420121. doi: 10.1073/pnas.2401420121. Epub 2024 Jul 12. Proc Natl Acad Sci U S A. 2024. PMID: 38995966 Free PMC article.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Dec 14;404(10470):2423-2436. doi: 10.1016/S0140-6736(24)01762-8. Epub 2024 Nov 21. Lancet. 2024. PMID: 39581202 Clinical Trial.
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S; ARTEMIS-UC Study Group. Sands BE, et al. N Engl J Med. 2024 Sep 26;391(12):1119-1129. doi: 10.1056/NEJMoa2314076. N Engl J Med. 2024. PMID: 39321363 Clinical Trial.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR; GALAXI-1 Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
30 results